# 1Florida Alzheimer's Disease Research Center Clinical Core

> **NIH NIH P30** · UNIVERSITY OF FLORIDA · 2022 · $2,007,554

## Abstract

The goal of the 1Florida ADRC is to advance the understanding of Alzheimer’s disease and Related Disorders
(ADRDs), especially in underrepresented minority groups. Among 370 participants currently recruited at Mount
Sinai Medical Center (MSMC), 60% are Hispanic, with a retention rate of ~80%, over 50% are normal or have
various stages of Mild Cognitive Impairment (MCI). Structural MRI has been obtained on 90% and amyloid PET
(aPET) scans on ~70% of participants (comprising 1/3 of all aPET scans in NACC). Autopsy has been obtained
on over 95% of those consented, including > 50% from Hispanic decedents. Novel neuropsychological
instruments in English and Spanish have been developed and utilized to detect cognitive impairment before it is
detectable by standard assessments. The effects of language, culture, acculturation and bilingualism among
minority groups on cognitive and functional performance, the demographic and genetic factors that affect the
threshold for amyloid positivity and the differential effect of APOE genotype on amyloid load in Hispanics versus
non-Hispanics have been studies in depth.
In the current P30 application, we propose to expand the clinical core to include MSMC as well as University of
Miami (UM), where recruitment and retention of AA participants has been very successful and expertise in
evaluating vascular comorbidities and contributions to dementia exists, and the University of Florida (UF),
Gainesville, where considerable expertise exists in evaluation and studies of Lewy Body Disease (LBD) and
early Parkinson’s disease. In total we propose to recruit 600 participants (~40% Hispanic, ~40% White non-
Hispanic [WNH], and ~20% AA), including 100 new participants at each of three sites and at least 200 follow-
ups at MSMC and 100 follow-ups each at UM and UF. All new participants will receive MRI and aPET scans.
Follow-up participants will also receive repeat MRI scans and most will receive aPET scans. Blood-based
biomarker assessments (Aβ42:40, NFL, and others) will be used to complement the imaging and
neuropsychological assessments.
Clinical Core activities will be integrated closely with ORE, REC, Biomarker and Pathology Cores, and
harmonized across the three clinical sites with respect to consistency of assessments, biospecimens, biomarker
studies, standardized implementation of all NACC modules, LBD and vascular assessments diagnostic
methodology. Utilization of elements of the NIA-AA Research Framework ATN classification (Amyloid, Tau,
Neurodegeneration) will be implemented. Methods and metrics will be used to ensure full integration between
the sites, including recruitment and enrollment for brain autopsies, which will be done at all three sites, with
correlation of imaging findings to regional brain pathology and structural changes. Qualified investigators and
the larger ADRD community will receive access to Clinical Core participants and their data and biospecimens
for research projects and education, training p...

## Key facts

- **NIH application ID:** 10413191
- **Project number:** 5P30AG066506-03
- **Recipient organization:** UNIVERSITY OF FLORIDA
- **Principal Investigator:** Ranjan Duara
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $2,007,554
- **Award type:** 5
- **Project period:** 2020-06-15 → 2025-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10413191

## Citation

> US National Institutes of Health, RePORTER application 10413191, 1Florida Alzheimer's Disease Research Center Clinical Core (5P30AG066506-03). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10413191. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*